Dublin, May 29, 2024 (GLOBE NEWSWIRE) -- The "Epilepsy Therapeutics Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The global epilepsy therapeutics market is forecasted to experience substantial growth from 2024 to 2034
This advancement is significantly driven by medical innovations such as the development of an implantable monitoring device by NYU Langone Health, supported by the National Institutes of Health. The high-density electrode device is designed to capture detailed brain activity during seizures and is expected to set a new benchmark in patient care upon its anticipated clinical commencement.
Tackling Socioeconomic and Technological Barriers
Accessibility and affordability of treatment remain critical concerns in epilepsy care. Addressing these socioeconomic disparities and ensuring equal access to leading-edge treatments are central to improving healthcare outcomes. The epilepsy therapeutics market faces multifaceted challenges, including the need for healthcare interventions that are economically and equitably sustainable. Telehealth services are part of promising strategies to bridge gaps in healthcare delivery.
Analyzing Market Dynamics and Prospects
The report suggests that stakeholders should consider various factors when analyzing the epilepsy therapeutics market. Questions addressing market evolution, the influence of drivers and restraints, and the anticipated growth of market segments are essential for comprehending the potential trajectory of this market.
Regional and National Market Forecasts Signify Growth
With detailed analysis across several geographic regions and countries, growth trends are anticipated in both established and emerging markets. North America and the Asia Pacific regions, in particular, are expected to contribute to the growth of the epilepsy therapeutics market owing to technological advancements and increasing healthcare expenditure.
Advancements and the Impact of COVID-19 on the Market
The report also underscores how the COVID-19 pandemic has influenced the epilepsy therapeutics market, impacting various recovery patterns. Adjustments in response to the pandemic are affecting industry trends and the market direction.
Emergence of New Therapeutics and Distribution Channels
Segments covering drug class and distribution channels are identified in the report, revealing trends in first, second, and third-generation drugs and the growing significance of online pharmacies as an emerging distribution channel. **Corporate Prospects in the Epilepsy Therapeutics Market**
With an overview of the competitive landscape, the epilepsy therapeutics market is seen as a space for existing companies and newcomers to grow and innovate. This evolving market landscape is set to redefine epilepsy care, shaped by unique insights and commercial prospects through to 2034.
Companies Featured
- Eisai, Inc.
- GlaxoSmithKline (GSK)
- GW Pharma
- Merk KGaA
- Neurocrine Biosciences, Inc.
- Novartis AG
- Ovid Therapeutics
- Pfizer Inc
- Praxis Precision Medicines
- Sanofi
- UCB S.A.
For more information about this report visit https://www.researchandmarkets.com/r/p6twx3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
